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Abstract A selective inhibitor of protein kinase C (PKC), Ro 
31-8220, blocks pleckstrin (P47) phosphorylation i  platelets ac- 
tivated with either ADP, ADP plus synthetic thromboxane ag- 
onist U46619 and ADP plus U46619 plus epinephrine, while 
inducing a weak inhibition of platelet aggregation, and no signif- 
icant effect on the fihrinogen binding. In platelets activated by 
U46619 alone, P47 phosphorylation, platelet aggregation, fibrin- 
ogen binding and serotonin release are all inhibited by Ro 31- 
8220. In the presence of an ADP scavenger system, U46619 
induces pleckstrin phosphorylation, serotonin release and calcium 
mobilization but not platelet aggregation and fihrinogen binding, 
unless epinephrine is added. In conclusion: (1) PKC activation is 
required for ADP secretion; (2) ADP or epinephrine are essential 
for fibrinogen receptor exposure induced by U46619; (3) fibrino- 
gen receptor exposure induced by ADP is independent of activa- 
tion of PKC. 
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1. Introduction 
Platelet aggregation involves exposure of fibrinogen recep- 
tors on the platelet surface induced by agonists such as ADP 
or thrombin acting through distinct receptors. Little is known 
about the signalling pathway that results in exposure of the 
fibrinogen receptor Gpl Ib- I I Ia  [1-3]. It is clear that protein 
kinase C (PKC) is important in secretion of ADP and PKC has 
been proposed to be directly involved in the process of fibrino- 
gen receptor exposure as well [4]. However, in a previous tudy 
we demonstrated that in suspensions of thrombin-degranulated 
platelets the exposure of Gpl Ib- I I Ia is dissociated from phos- 
pholipase C activation, and because PLC activation produces 
diacylglycerol, a PKC activator, we suggested that the activa- 
tion of PKC is not important in inducing fibrinogen binding [3]. 
Other studies using complement-permeabilized platelets dem- 
onstrated a role for G proteins and protein tyrosine phospho- 
rylation, which may be involved in fibrinogen receptor expo- 
sure by an undetermined mechanism [5]. Moreover, other 
authors demonstrated that the inhibition of the small GTP- 
binding protein rho-A with Botulinum C3 partially inhibits 
thrombin induced aggregation [6]. 
Ro 31-8220 is a more specifc inhibitor of PKC activation 
than other agents such as staurosporine [7,8]. 
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The present study examines the separate ffects of Ro 31- 
8220 on agonist-induced calcium response, ADP secretion and 
subsequent exposure of fibrinogen receptors and aggregation. 
The results support he idea that while protein kinase C activa- 
tion is important for ADP secretion it is not important for 
exposure of fibrinogen receptors and aggregation. 
2. Materials and methods 
Blood samples, using acid/citrate/dextrose (ACD) [9] as anticoagu- 
lant (1 : 7 v/v), were obtained from healthy volunteers who denied hav- 
ing taken any drugs in the two weeks before blood sampling. 
Platelet Rich Plasma (PRP) was obtained after centrifugation 
(180×g for 15 min), then was centrifuged (800xg for 20 min) to 
concentrate he platelets (6 × 108 cells/ml). The concentrated platelets 
were incubated with [32p]orthophosphoric acid (ICN, Costa Mesa, CA, 
USA) (0.25 mCi/ml of the platelet suspension) or with [14C]5-hy- 
droxytryptamine ([14C]5HT, 1/IM) (ICN) for 1 h at 37°C, or with 3/tM 
Fura-2-AM (Moleculare Probes) for 30 min at 37°C and 15 min at 
room temperature. Excess [32p]phosphate, [~4C]5HT and Fura-2-AM 
were separated from the platelets by gel-filtration (gel-filtered-platelets, 
GFP) on Sepharose 2B-CL (Pharmacia, Uppsala, Sweden) using Ca 2+- 
free Tyrode's buffer containing 0.2% albumin (Bovine serum albumin 
fraction V - BSA), 0.1% glucose and 10 mM HEPES (pH 7.35) (Sigma, 
Chemicals Co., St. Louis, MO, USA). 
In some experiments platelets were aspirinated by treatment of the 
concentrated PRP with aspirin (1 mM at 37°C for 15 min). 
In all experiments toinhibit PKC activity the platelets were incubated 
for 3 min with 10/tM Ro 31-8220 (generous gift of Dr. G. Lawton, 
Roche Research Centre, Welwyn Garden City, Herts, UK); to scaven- 
ger ADP released from the platelets creatine phosphate (20-40 mM) 
and creatine kinase (50-100 U/ml) (CP/CPK) were used; both inhibitors 
were used before the addition of agonists. 
2.1. Platelet aggregation 
In vitro platelet aggregation was evaluated according to Born [10], 
in a four sample Menarini (Florence, Italy) 3210 Aggrecorder, using 
siliconized glass cuvets, at 37°C and under continuous stirring at 1000 
rpm. ADP (10/tM), Epinephrine (10/~M) (both from Menarini) and 
U46619 (1-10/.tM) (Sigma), either alone or in combination, were used 
as aggregation i ducers. Platelets were resuspended at the concentra- 
tion of 2.5 x 108/ml and fibrinogen (1 mg/ml) was added before the 
agonists. 
2.2. Fibrinogen binding 
Immediately after agonist activation GFP (2.5 x 108/ml) were incu- 
bated with 0.18 mM [~zsI]fibrinogen (ICN). To measure nonspecific t25I 
binding, parallel samples were incubated with 15 mM of unlabelled 
human fibrinogen in the presence of [~25I]fibrinogen at the same concen- 
tration as above. 
To remove the unbound [~25I]fibrinogen the platelet suspension was 
layered over a mixture of silicon oils (Dow-Corning 550: 200; 5:1) in 
binding tubes and centrifuged in a microfuge for 1 min at 12,000 x g. 
The tips of the tube were cut off and the radioactivities ofthe pellet and 
supernatant were counted using a 7/counter (Cobra, Camberra Pack- 
ard, Meriden, USA) [3]. 
The data are expressed as the mean + S.E.M. of the difference incpm 
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Fig. 1. Platelet aggregation patterns in response to ADP alone (20/aM), ADP plus U46619 (10/aM and 1/aM, respectively) and MIX (ADP 10/aM, 
epinephrine 10/aM and U46619 1/aM), in control GFP (upper curves) and after Ro 31-8220 treatment (lower curves). The figure is representative 
of four experiments. 
between the platelet suspension incubated with [~25I]fibrinogen alone 
and that incubated with [125I]fibrinogen plus unlabelled fibrinogen. 
2.3. PKC activation 
PKC activation was evaluated by analyzing the phosphorylation f
pleckstrin (P47), the major PKC substrate in platelets, using 10 or 
12.5% acrylamide in SDS-PAGE [11] of 32p-labelled platelets ampled 
10 rain after activation. 
2.4. Platelet secretion 
Platelet secretion was evaluated by measuring the release of[~4C]5HT 
and expressed as the percentage of the total [14C]5HT content. 
The activation of labelled [14C]5HT platelets was stopped after two 
min with formaldehyde/EDTA according to the method of Costa and 
Murphy [12]; after centrifugation (5000 x g for 1 min) the radioactivity 
of the supernatant was measured using a LKB (Pharmacia, Uppsala, 
Sweden) liquid scintillation counter. 
2.5. Changes in intracellular calcium concentrations 
The changes in intracellular calcium concentrations were monitored 
by using the fluorescence dye Fura-2. The agonists were added to 
Fura-2-1oaded platelets into cuvettes thermostatically regulated at 
37°C and stirred continuously. Then the fluorescence changes were 
monitored with a Kontron SFM 25 fluorimeter, set at 340 nM excita- 
tion and 510 nM emission. In order to convert fluorescence measure- 
ments into Ca 2+ concentrations, Fm~, was determined after the addition 
of digitonin (50/aM) (Sigma) in the presence of EGTA (2 mM) and Tris 
base (20 raM); Fmax was measured by the addition of excess CaC12 
(10 mM). Differences in free calcium concentrations between the un- 
stimulated and stimulated platelets were calculated using the measured 
values and a Kd of 224 nM after correction for extracellular dye [13], 
and expressed as AnM. 
3. Results and discussion 
The selective protein kinase C inhibitor Ro 31-8220 (10/zM) 
completely inhibited phosphorylation of pleckstrin (P47), the 
major PKC substrate in platelets, induced by ADP (20/~M) 
added alone or in combination with the synthetic thromboxane 
receptor agonist U46619 (1 ¢tM). Ro 31-8220 (10/zM) also 
inhibited P47 phosphorylation i duced by a mixture of ADP, 
epinephrine and U46619 (10, 10 and 1 ItM, respectively) (MIX) 
(data not shown). 
The data can be compared with aggregation studies shown 
in Fig. 1. A weak inhibition of platelet aggregation was present 
after adding Ro 31-8220 when the platelets were stimulated 
with ADP (20 /~M) (42.7 + 10.5% versus 55.8 + 11.7%), or 
ADP plus U46619 (58.9 + 8.9 versus 72.7 + 11.3) or with 
U46619 plus epinephrine (66.0 + 10.1 versus 76.5 + 7.8). Using 
aspirinated platelets aggregation was similar either in control 
platelets or in Ro 31-8220 treated platelets (data not shown), 
with all the agonists used. Moreover Ro 31-8220 did not induce 
any statistically significant inhibition of the fibrinogen binding 
after three min of platelet activation with MIX, U46619 plus 
ADP and ADP alone (Fig. 2). 
These results are in agreement with those of Walker and 
Watson [7] who also showed that Ro 31-8220 completely inhib- 
ited thrombin-induced (1 U/ml) phosphorylation of pleckstrin 
while aggregation was only slowed slightly. 
Ro 31-8220 did not change the intraplatelet calcium response 
to all the agonists used, as shown in Fig. 3. Conversely, Ro 
31-8220 inhibited the serotonin release induced by all the ag- 
onists used (data not shown). 
In contrast, Ro 31-8220 inhibited platelet P47 phosphoryla- 
tion (data not shown) as well as platelet aggregation (Fig. 4) and 
fibrinogen binding (Fig. 5) induced by the thromboxane analog, 
U46619. This result may be explained if one assumes that se- 
creted ADP is essential for thromboxane-induced exposure of 
fibrinogen receptors. Since Ro 31-8220 inhibits the release of 
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Fig. 2. Specific [~2~l]fibrinogen bi ding in control GFP and in platelets 
treated with Ro 31-8220 after activation with agonists. The results are 
expressed as mean + S.E.M. of the cpm measured in the platelet pellet 
from six different experiments. The agonist concentrations u ed were 
the same as in Fig. 1. 
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Fig. 3. A representative pattern of four experiments performed of the 
changes in intracellular calcium concentration in Ro 31-8220 treated (b) 
and control (a) Fura-2 loaded GFP in response to different agonists. 
The agonist concentrations used were the same as in Fig. 1. 
endogenous ADP, as demonstrated by the reduction of 
[]4C]5HT release (8.3 + 1.1% versus 78.1 _+ 11.4%), it would 
inhibit if neither ADP nor epinephrine were added. This hy- 
pothesis is supported by experiments demonstrating that the 
addition of the ADP scavenger system creatine phosphate and 
creatine kinase (CP/CPK), inhibits thromboxane-induced 
platelet aggregation i normal platelets [14]; moreover, we pre- 
viously found that in thrombin-degranulated platelets, U46619 
does not induce platelet aggregation unless ADP or epinephrine 
was present [15]. Furthermore, we have determined whether 
PKC was activated in gel-filtered platelets stimulated with 
U46619 in the presence of CP/CPK (20-40 mM and 50-100 
U/ml). The presence of CP/CPK did not inhibit U46619 (1 mM) 
induced P47 phosphorylation (data not shown), serotonin re- 
lease (72.5 + 15.7% versus 78.1 + 11.4) or intracellular calcium 
mobilization (Fig. 4) while completely inhibiting aggregation 
(Fig. 5) and fibrinogen binding (Fig. 6). Similar results were 
obtained if the concentration of U46619 was increased to 10 
mM. When epinephrine 20 /IM was added with U46619 in 
CP/CPK treated platelets the aggregation was restored (43 + 11 
min 
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Fig. 4. Platelet aggregation patterns in response to U46619 (1 HM) in 
control platelets, in Ro 31-8220 treated platelets and in ADP scavenger 
system CP/CPK-treated platelets. The figure is representative of five 
experiments. 
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Fig. 5. Specific [~zsI]fibrinogen binding in control GFP, in U46619- 
stimulated platelets, and in U46619 stimulated platelets after treatment 
with Ro 31-8220 or with the ADP scavenger system CP/CPK. The 
results are expressed as mean + S.E.M. of the cpm measured in the 
platelet pellet from six different experiments. 
maximum percent). Thus epinephrine can substitute for ADP 
in producing fibrinogen receptor activation. 
In support of these results, Savi et al. [16] in studies of platelet 
activation by thrombin receptor activating peptide (TRAP) 
found that TRAP-induced platelet aggregation was abolished 
when CP/CPK (10 mM and 80 U/ml respectively) were added 
to the suspension. The only difference between the behaviour 
of U46619 and TRAP was if higher concentration of TRAP 
was added the inhibitory effect of ADP removal was reduced. 
In conclusion, our results support he idea that while activa- 
tion of protein kinase C in platelets is important for secretion, 
it is not required for platelet aggregation. Exposure of the 
fibrinogen receptor seems to be independent of an increase in 
intracellular Ca 2+ since U46619 which induces an increase in 
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Fig. 6. Changes in intracellular calcium concentration in control (a), Ro 
31-8220 treated (b) and CP/CPK treated (c) Fura-2 loaded GFP in 
response to U46619 (1/IM). The figure is representative of five exper- 
iments. 
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intracellular Ca 2÷ independently of ADP or epinephrine does 
not induce a concomitant platelet aggregation. 
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